Virtual CME Program
1.00 CME/CE Credit
How I Manage Statin Reluctance and Other Challenges in Lipid Therapy
Multiple lines of evidence have demonstrated that LDL-C and apoB-containing lipoproteins are causally related to atherosclerotic cardiovascular risk (ASCVD). Statins remain the first line treatment for the primary and secondary prevention of ASCVD, but many high-risk patients remain above LDL-C goal. Statin reluctance or perceived statin intolerance can be a barrier to effectively managing lipids for ASCVD risk reduction. This talk will discuss the approach to treating the patient with statin-reluctance or statin-intolerance, to help approve adherence to statin therapy, as well as the role of non-statin therapies for LDL-C lowering, pipeline.
CME/CE Information
1.00 AMA PRA Category 1 Credits™, 1.00 ABIM MOC or 1.00 AANP, including 1.00 AANP Pharm
Release Date: 3/5/2025
Expiration Date: 6/3/2025
Topics
Learning Objectives
- Review low density lipoprotein cholesterol (LDL-C) as a primary causal factor for the development of atherosclerotic cardiovascular disease (ASCVD) and thus a central target for ASCVD prevention, with statin therapy being the 1st line pharmacotherapy for ASCVD prevention.
- Discuss prevalence and risk factors for statin intolerance
- Review the National Lipid Association definition of statin intolerance
- Examine approaches to the patient with statin reluctance or statin intolerance to improve adherence
- Discuss non-statin options for LDL-C lowering if patient is unable to achieve LDL-C goal on maximally tolerated statin therapy
Faculty
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Professor of Medicine
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins School of Medicine
Co-Editor in Chief, the American Journal of Preventive Cardiology
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC: Consultant for Arrowhead, Ionis, Merck, New Amsterdam, Astra Zeneca, Amgen, Esperion, Novartis, Eli Lilly, Novo Nordisk, Zoll
Peter Libby, MD: Consultant for Astra Zeneca, Amgen, Baim Therapeutics, Esperion, Genentech, Kancera, Kowa, MedImmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer, Sanofi Regeneron, Advisor for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CLS Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, MedImmune, Novartis, PlaqueTec, TenSixteen Bio, Soley Therapeutics, Xbiotech Inc, Researcher for Novo Nordisk, Genentech, Novartis, Advisory for Xbiotech Inc
Non-faculty contributors and others involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
Designation Statement
This activity is approved for 1.00 contact hour of continuing education, which includes 1.00 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.